Zachary Bellman - An unwatched pot never boils

Medical cannabis suffers from a lack of reliable product quality control and consistent labeling. Rigorous chemical analysis, such as NMR testing, reveals significant discrepancies between claimed and actual cannabinoid content in commercial CBD oils and other cannabis extracts. This market instability undermines consumer safety and highlights the urgent need for standardized oversight as cannabis transitions into a more conventional pharmaceutical context. Increased attention to product standards and consumer education is essential to address these regulatory gaps. A shift toward stringent approval frameworks like the Traditional Herbal Registration scheme could professionalize the industry and ensure that products meet specific quality metrics. Such improvements would foster greater transparency, better health outcomes for patients, and a more structured pharmaceutical market.